Macrogenics Return on Equity

Macrogenics (MGNX) currently reports a ROE of -204.72%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Macrogenics's ROE history and peer comparisons.

Macrogenics's ROE of -204.72% is lower than the Healthcare sector average of 13.1%. That is roughly 1662.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Macrogenics's current -204.72% should be judged against Healthcare norms (sector average: 13.1%) and against MGNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -204.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Macrogenics, and consider following MGNX for alerts when major investors trade the stock.

Macrogenics is classified in the Healthcare sector. On ROE, it currently shows -204.72% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MGNX with unrelated industries.